Wei Zheng, MD, PhD, MPH, Anne Potter Wilson Professor of Medicine, has been named associate director for Population Sciences Research at Vanderbilt- Ingram Cancer Center (VICC).

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.